Clinical Trials Directory

Trials / Unknown

UnknownNCT05923515

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
78 (estimated)
Sponsor
Jemincare · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

A Phase I, Open, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Detailed description

Primary objectives: To evaluate the safety and tolerability of JMKX000197 injection in the treatment of patients with malignant pleural effusion, explore DLT of JMKX000197 treatment, and determine MTD and RP2D. Secondary objectives: To evaluate the pharmacokinetic (PK)/pharmacokinetic (PD) characteristics of JMKX000197 injection in the treatment of patients with malignant pleural effusion; To evaluate preliminarily efficacy of JMKX000197 injection in patients with malignant pleural effusion; To evaluate the drug metabolic transformation of JMKX000197 injection.

Conditions

Interventions

TypeNameDescription
DRUGJMKX000197for injection

Timeline

Start date
2023-05-22
Primary completion
2025-04-30
Completion
2025-05-01
First posted
2023-06-28
Last updated
2023-06-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05923515. Inclusion in this directory is not an endorsement.

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion (NCT05923515) · Clinical Trials Directory